Bausch + Lomb Reports $5.101 Billion Revenue for Fiscal Year 2025, Net Loss of $360 Million

Bausch + Lomb Corporation, a global eye health company, reported total revenues of $5.101 billion for the fiscal year ending December 31, 2025, marking a 6% increase compared to $4.791 billion in 2024. This growth was primarily driven by increased sales volumes across all three of its operating segments: Vision Care, Pharmaceuticals, and Surgical. The company attributed the revenue increase to higher volumes of $301 million, a favorable impact from foreign currencies of $58 million, and incremental sales from acquisitions of $16 million. These gains were partially offset by decreased net realized pricing of $53 million, mainly in the Pharmaceuticals segment, and a $12 million impact from divestitures and discontinuations, primarily in the Vision Care segment.

The Vision Care segment saw revenues rise to $2.923 billion, a 7% increase from $2.739 billion in the previous year, fueled by strong performance in its dry eye portfolio, Lumify®, PreserVision®, SiHy Daily lenses, and Bausch + Lomb Ultra® contact lenses. The Pharmaceuticals segment also experienced growth, with revenues reaching $1.284 billion, a 6% increase from $1.209 billion in 2024, driven by MIEBO® and international sales, although this was partially offset by declines in the U.S. generics business and pricing pressures. The Surgical segment's revenue increased to $894 million, a 6% rise from $843 million in 2024, due to higher demand for consumables and implantables, particularly its premium IOL portfolio, and increased equipment sales.

Despite the revenue growth, Bausch + Lomb reported a net loss attributable to the corporation of $360 million for 2025, compared to a net loss of $317 million in 2024. This decrease in profitability was primarily due to an increase in selling, general, and administrative expenses, as well as higher interest expenses, partially offset by a decrease in the provision for income taxes. The company's cost of goods sold also increased by 9%, driven by higher volumes, manufacturing variances, and royalties.

Looking ahead, Bausch + Lomb is focused on advancing its pipeline of over 60 R&D projects, including new contact lenses for myopia, next-generation cataract equipment, premium IOLs, and investigational treatments for dry eye. The company anticipates launching Lumify® next generation and AREDS3 vitamins in 2026, and is progressing with clinical studies for dual-action lifitegrast and glaucoma neuroprotection therapies. The company also expects to submit ELIOS® for U.S. approval in the first half of 2026. Bausch + Lomb's strategic priorities include leveraging its expertise in eye health, increasing product adoption, continuously investing in its product portfolio, and optimizing business operations.